Recently, an advisory committee of the U.S. Food and Drug Administration voted in favor of requiring additional trial data in order for a China-trialed medicine to obtain FDA approval. This decision could have major implications for future regulatory approval applications for medicines developed in China. The FDA's positions and the considerations of the committee members are summarized below.

You don't have access to this post on China Trade Monitor at the moment, but if you upgrade your account you'll be able to see the whole thing, as well as all the other posts in the archive! Subscribing only takes a few seconds and will give you immediate access.

This post is for subscribers only

Subscribe now